Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 717919, 9 pages
Review Article

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077
2Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599

Received 17 March 2014; Accepted 20 May 2014; Published 17 June 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 P. J. Teoh and W. J. Chng. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells. For instance, promising preclinical results have steered both nutlin-3 and PRIMA-1 into phase I/II clinical trials. This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53-based therapies that are being utilized in the clinic. Finally, we discuss the potential and promise that the novel small molecules possess for clinical application in improving the treatment outcome of myeloma.